August 21, 2014

Advertisement

August 20, 2014

August 19, 2014

August 18, 2014

Can Human Genes Be Patented?

On Monday, April 15, 2013, the United States Supreme Court will hear a challenge to Myriad’s patents on two isolated genes, BRCA 1 and BRCA 2.  The two patented genes, when mutated, can put women at higher risk for breast and ovarian cancer.  With the granted patents, Myriad has secured its position as the only place to go for testing of these genes, with a high price tag.  Scientists, researchers and patients who believe the patents are blocking further research and limiting the availability of testing, are leading the challenge against Myriad’s patents.

Below is an in-depth look at patent eligibility and the challenge against Myriad, from Mercedes Meyer (may take a few moments to load):

Download (PPT, 11.27MB)

©2014 Drinker Biddle & Reath LLP. All Rights Reserved

TRENDING LEGAL ANALYSIS


About this Author

Partner

Mercedes K. Meyer, Ph.D., a partner in the Intellectual Property Practice Group, collaborates with her biotechnology and pharmaceutical clients on their patent portfolio strategy.  She has an extensive biotechnology and pharmaceutical patent prosecution practice.

Mercedes publishes in the LIfe Sciences Now blog.

202-842-8821

More From This Author